Sab Biotherapeutics, INC Schedule 13D activist filings

RA Capital Management and its affiliates have updated their Schedule 13D filing to reflect a change in their beneficial ownership percentage of SAB Biotherapeutics, Inc. due to an increase in the issuer's outstanding common stock.

RA Capital Management and its affiliates increased their beneficial ownership in SAB Biotherapeutics, Inc. to 9.9% through the acquisition of pre-funded warrants.

RA Capital Management, L.P. and its affiliates have acquired 9.9% of SAB Biotherapeutics' common stock following a private placement and preferred stock conversion.